Eyelid Lentigo Maligna Treated With Imiquimod 5%: Should We Fear of Ocular Side Effects?

Eyelid Lentigo Maligna Treated With Imiquimod 5%: Should We Fear of Ocular Side Effects?

Authors

  • Claudio Conforti Dermatology Clinic, Maggiore Hospital of Trieste, Trieste, Italy
  • Carmen Dell'aquila Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy
  • Daniele Tognetto Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy
  • Iris Zalaudek Dermatology Clinic, Maggiore Hospital of Trieste, Trieste, Italy
  • Nicola di Meo Dermatology Clinic, Maggiore Hospital of Trieste, Trieste, Italy

References

Lallas A, Moscarella E, Kittler H, et al. Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna. Br J Dermatol. 2021;185(3):675-677. DOI: 10.1111/bjd.20407. PMID: 33894006.

Hamilko de Barros M, Conforti C, Giuffrida R, Seabra Resende FS, Di Meo N, Zalaudek I. Clinical usefulness of dermoscopy in the management of lentigo maligna melanoma treated with topical imiquimod: A case report. Dermatol Ther. 2019;32(5):e13048. DOI: 10.1111/dth.13048. PMID: 31365164.

O'Neill J, Ayers D, Kenealy J. Periocular lentigo maligna treated with imiquimod. J Dermatolog Treat. 2011;22(2):109-112. DOI: 10.3109/09546630903559798. PMID: 20666668.

Elia MD, Lally SE, Hanlon AM, et al. Periocular Melanoma In Situ Treated With Imiquimod. Ophthalmic Plast Reconstr Surg. 2016 Sep-Oct;32(5):371-373. DOI: 10.1097/IOP.0000000000000554. PMID: 26325381.

Murchison AP, Washington CV, Soloman AR, Bernardino CR. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatol Surg. 2007;33:1136–1138. DOI: 10.1111/j.1524-4725.2007.33232.x. PMID: 17760609.

Downloads

Published

2023-01-31

Issue

2023 Vol 13, No 1 | January

Section

Letter to the Editor

License

Copyright (c) 2023 Claudio Conforti, Carmen Dell'aquila, Daniele Tognetto, Iris Zalaudek, Nicola di Meo

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Conforti C, Dell'aquila C, Tognetto D, Zalaudek I, di Meo N. Eyelid Lentigo Maligna Treated With Imiquimod 5%: Should We Fear of Ocular Side Effects?. Dermatol Pract Concept. 2023;13(1):e2023042. doi:10.5826/dpc.1301a42

Share

Crossref
Scopus
Google Scholar
Europe PMC